al. investigated the association between the expression of TROP2 and the tumor immune microenvironment, including PD-L1, CD3, and CD8, using IHC in CC, reported that expression of TROP2 in CC is associated with increased levels of intratumorally tumor-infiltrating lymphocytes, and indicated that the potential of TROP2 targeted therapy in combination with immune checkpoint inhibitors [96]. Here, TACSTD2 is linked to neoplasm.